![[ Back to EurekAlert! ]](http://www.eurekalert.org/images/back2e.gif){kind=small}
Public release date: 17-Sep-2012[ | E-mail |
Share ] Contact: Nils Ekstrm
nils.ekstrom@gu.se
46-702-890-121
University of Gothenburg
The antidiabetic drug metformin is not prescribed for patients with reduced kidney function because the risk of adverse effects has been regarded as unacceptably high. A study at Sahlgrenska Academy, University of Gothenburg, Sweden, has found that the risks have been substantially overrated. As a result, many more patients with diabetes may be able to enjoy the benefits of the medication.
Type 2 diabetes, a very common condition, is increasingly prevalent around the world. Keeping diabetes under control and preventing complications requires not only lifestyle changes, but drug therapy to reduce blood glucose levels.
Among the most effective and frequently prescribed antidiabetics is metformin, which has been shown in a number of studies to lower the risk of death from cardiovascular disease. Because the drug has been considered causing an increased risk of developing a rare but life-threatening adverse effect known as lactic acidosis, it is not prescribed for patients with reduced kidney function.
Researchers at Sahlgrenska Academy, University of Gothenburg and Uppsala University have conducted a study involving 51,700 patients with type 2 diabetes from the Swedish national diabetes register and found that the risks are exaggerated.
The Gothenburg study shows that metformin is more effective than other glucose lowering drugs when it comes to reducing the risk of cardiovascular disease, serious infection and death in patients with normal kidney function, but also in patients with mild kidney impairment.
"Furthermore, patients with mild to moderate kidney impairment do not run an elevated risk of adverse effects from metformin,"says Nils Ekstrm, a researcher at Sahlgrenska Academy. "Thus, the drug can be prescribed for many more patients with diabetes than is currently the case."
According to Nils Ekstrm, a number of other countries already recommend metformin for patients with mild kidney impairment. "It is important to keep in mind that the results are for patients with mild to moderate kidney impairment," he says. "Metformin still cannot be recommended for patients with severe kidney impairment and should be prescribed with great caution for those patients. During periods of acute illness with dehydration, metformin should never be used"
###
BMJ Open published the article, "Effectiveness and Safety of Metformin in 51,675 Patients with Type 2 Diabetes and Different Levels of Renal Function: a Cohort Study from the Swedish National Diabetes Register" in July.
Contacts:
Nils Ekstrm, Medical Doctor, Department of Medicine, Sahlgrenska University Hospital
Phone +46 70 289 01 21
nils.ekstrom@gu.se
Soffia Gudbjrnsdottir, Associate professor and Senior Physician, National Diabetes Register and Department of Medicine, Sahlgrenska University Hospital
Phone +46 707 777 32
Bjrn Eliasson, Adjunct Professor and Senior Physician, Department of Medicine, Sahlgrenska University Hospital
Phone +46 70 604 23 80
bjorn.eliasson @gu.se
[ | E-mail | Share ] ?
AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert! system.
Public release date: 17-Sep-2012[ | E-mail |
Share ] Contact: Nils Ekstrm
nils.ekstrom@gu.se
46-702-890-121
University of Gothenburg
The antidiabetic drug metformin is not prescribed for patients with reduced kidney function because the risk of adverse effects has been regarded as unacceptably high. A study at Sahlgrenska Academy, University of Gothenburg, Sweden, has found that the risks have been substantially overrated. As a result, many more patients with diabetes may be able to enjoy the benefits of the medication.
Type 2 diabetes, a very common condition, is increasingly prevalent around the world. Keeping diabetes under control and preventing complications requires not only lifestyle changes, but drug therapy to reduce blood glucose levels.
Among the most effective and frequently prescribed antidiabetics is metformin, which has been shown in a number of studies to lower the risk of death from cardiovascular disease. Because the drug has been considered causing an increased risk of developing a rare but life-threatening adverse effect known as lactic acidosis, it is not prescribed for patients with reduced kidney function.
Researchers at Sahlgrenska Academy, University of Gothenburg and Uppsala University have conducted a study involving 51,700 patients with type 2 diabetes from the Swedish national diabetes register and found that the risks are exaggerated.
The Gothenburg study shows that metformin is more effective than other glucose lowering drugs when it comes to reducing the risk of cardiovascular disease, serious infection and death in patients with normal kidney function, but also in patients with mild kidney impairment.
"Furthermore, patients with mild to moderate kidney impairment do not run an elevated risk of adverse effects from metformin,"says Nils Ekstrm, a researcher at Sahlgrenska Academy. "Thus, the drug can be prescribed for many more patients with diabetes than is currently the case."
According to Nils Ekstrm, a number of other countries already recommend metformin for patients with mild kidney impairment. "It is important to keep in mind that the results are for patients with mild to moderate kidney impairment," he says. "Metformin still cannot be recommended for patients with severe kidney impairment and should be prescribed with great caution for those patients. During periods of acute illness with dehydration, metformin should never be used"
###
BMJ Open published the article, "Effectiveness and Safety of Metformin in 51,675 Patients with Type 2 Diabetes and Different Levels of Renal Function: a Cohort Study from the Swedish National Diabetes Register" in July.
Contacts:
Nils Ekstrm, Medical Doctor, Department of Medicine, Sahlgrenska University Hospital
Phone +46 70 289 01 21
nils.ekstrom@gu.se
Soffia Gudbjrnsdottir, Associate professor and Senior Physician, National Diabetes Register and Department of Medicine, Sahlgrenska University Hospital
Phone +46 707 777 32
Bjrn Eliasson, Adjunct Professor and Senior Physician, Department of Medicine, Sahlgrenska University Hospital
Phone +46 70 604 23 80
bjorn.eliasson @gu.se
[ | E-mail | Share ] ?
AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert! system.
Source: http://www.eurekalert.org/pub_releases/2012-09/uog-cmp091712.php
did groundhog see his shadow soul train don cornelius rod parsley barry sanders jr nick carter sister recruiting rankings san onofre
No comments:
Post a Comment